Related Experiment Videos
Fosfomycin therapy of experimental infections in mice
Zentralblatt Fur Bakteriologie, Parasitenkunde, Infektionskrankheiten Und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie Und Parasitologie
|March 1, 1979
Abstract:
Fosfomycin inhibits the development of severe pyogenic infection by Staphylococcus aureus in kidneys if administered during establishment of infection. It inhibits the development of lethal infection by Escherichia coli. It has a positive therapeutic effect on listeria infection in mice even with a fosfomycin resistant mutant.
Insights
Fosfomycin effectively treats severe Staphylococcus aureus kidney infections and lethal Escherichia coli infections. It also shows therapeutic benefits for listeria infections, even against resistant strains.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Bacterial infections pose significant public health challenges.
- Antibiotic resistance is a growing concern in treating infections.
- Staphylococcus aureus, Escherichia coli, and Listeria are key pathogens.
Purpose of the Study:
- To evaluate the efficacy of fosfomycin against severe bacterial infections.
- To assess fosfomycin's activity in the context of Staphylococcus aureus, Escherichia coli, and Listeria infections.
- To investigate fosfomycin's effectiveness against antibiotic-resistant bacterial strains.
Main Methods:
- Animal models were used to simulate pyogenic kidney infections by Staphylococcus aureus.
- The inhibitory effects of fosfomycin on lethal Escherichia coli infections were examined.
- Therapeutic outcomes of fosfomycin treatment for listeria infection in mice, including against a resistant mutant, were assessed.
Main Results:
- Fosfomycin administration inhibited the development of severe Staphylococcus aureus pyogenic kidney infections.
- Fosfomycin demonstrated efficacy in preventing lethal infections caused by Escherichia coli.
- Positive therapeutic effects were observed in listeria-infected mice treated with fosfomycin, even when facing a resistant mutant.
Conclusions:
- Fosfomycin is a potent agent against severe Staphylococcus aureus and Escherichia coli infections.
- The antibiotic exhibits therapeutic value in treating listeria infections, including those with resistance.
- Fosfomycin represents a promising treatment option for various bacterial infections.